Related Experiment Video
Updated: May 1, 2026
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
Effect of inhaled anticholinergics on bronchial secretions: a systematic review
Leonardo Arzayus-Patiño1,2, José Julián Bernal-Sanchez1,2, Valeria Pérez-Hortua3,4
1Facultad de Salud, Programa de Fisioterapia, Universidad Santiago de Cali, Cali, Colombia.
Background:
Inhaled anticholinergics are commonly used in chronic respiratory diseases with the intention of reducing bronchial secretions in addition to their bronchodilatory effects. However, evidence regarding their direct influence on mucus production and clearance remains limited and fragmented. This study aimed to identify, evaluate, and synthesize the available evidence on the effects of inhaled and nebulized anticholinergics on mucus volume, rheological properties, mucociliary clearance, cough, and pulmonary function in adults.
Methods:
A systematic review was conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD42024575999). Comprehensive searches were performed in PubMed, OVID, Embase, SciELO, EBSCO, ScienceDirect, and Cochrane Library without date restrictions. Randomized and non-randomized studies assessing inhaled or nebulized anticholinergics were included. Risk of bias was evaluated using the RoB 2 and ROBINS-I tools.
Results:
Out of 2,449 records identified, eight studies comprising 403 participants met the inclusion criteria. Under stable clinical conditions, inhaled ipratropium and tiotropium showed no significant changes in sputum volume, viscosity, or mucociliary clearance compared with placebo. In acute or procedural settings, such as bronchoscopy, nebulized ipratropium was associated with a reduction in bronchial secretion grade and cough frequency. Tiotropium treatment demonstrated decreases in sputum solid fraction and mucin content (MUC5AC and MUC5B). None of the included studies reported impairment of mucociliary clearance or serious adverse events related to treatment.
Conclusion:
Current evidence does not demonstrate a consistent effect of inhaled or nebulized anticholinergics on sustained reduction of bronchial secretions. However, their use does not appear to cause adverse changes in mucus production or clearance and may induce transient effects during acute cholinergic stimulation. Overall, the findings support a favorable safety profile of these agents regarding airway secretion management.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024575999.
Related Concept Videos
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:24Cholinergic Antagonists: Pharmacokinetics
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...